Лефлуномид Drug photo

The description is actual on 24.05.2016

  • Latin name: Leflunomide
  • ATH code: L04AA13
  • Active ingredient: Leflunomid (Leflunomide)
  • Producer: Formosa Laboratories Inc. (Taiwan), Alembic Pharmaceutical Limited (India), Technology of drugs, Farmoslavl of closed joint stock company, Berezovsky pharmaceutical plant (Russia)


The following substances are a part of drug: leflunomid, hypro rod, calcium hydrophosphate dihydrate, corn starch, croscarmellose sodium, magnesium stearate, microcrystallic cellulose, selekoat, macrogoal, titanium dioxide.

Release form

Tablets biconvex a round form in a film cover in the blister on 10, 20 and 100 mg in cardboard packaging No. 30.

Pharmacological action

Immunodepressive, antirheumatic, antiinflammatory, anti-proliferative.

Pharmacodynamics and pharmacokinetics


The drug having immunomodulatory, anti-proliferative, antiinflammatory and anti-proliferative effect. Slows down process of proliferation and formation of DNA of T lymphocytes. The active metabolite of drug (A77172), destroys enzyme degidroorotat a dehydrogenase.


Absorption of drug after intake makes about 90%, at the same time, meal does not influence absorption of a leflunomid.

Drug is quickly metabolized in a liver and an intestinal wall to the main metabolite (A771726) and several minor. Cmax of the main metabolite after the dose accepted once is reached within a day. In blood contacts albumine. The untied fraction makes only 0.62%. Removal of the main metabolite slow, an elimination half-life — about 2 weeks.

Indications to use

  • as the main remedy in therapy of a pseudorheumatism in an active form for stopping of symptomatology of a disease and a delay of process of structural injuries of joints;
  • psoriasis arthritis in an active form.


Immunodeficiency, liver diseases, heavy anemia or heavy disturbances of a marrowy hemopoiesis, thrombocytopenia, leukopenia, heavy renal failure, the expressed heavy hypoproteinemia, till 18 flyings, a lactation, pregnancy, hypersensitivity to drug.

Side effects

Increase of the ABP, nausea, vomiting, aphthous stomatitis, diarrhea, abdominal pains, anorexia, tendovaginitis, rupture of sheaves, eczema, hair loss, xeroderma, local allergic reactions, rhinitis, pneumonia, hypophosphatemia, lipidemia.

Leflunomid, application instruction (Way and dosage)

Leflunomid 20 mg to swallow of tablets entirely, to accept without binding by the time of meal, washing down with water.

To begin treatment with administration of drug in a shock dose 100 mg a day for once for three days. Further — the supporting dosage:

  • at a pseudorheumatism of 10 mg — 20 mg of drug once a day;
  • at psoriasis arthritis in a dosage of 20 mg of 1 times a day.

The effect is shown in 1-1,5 months and further can increase till 6 months. To patients 65 years are more senior than any correction of a dose it is not required.


Data are absent.


Leflunomid at the accompanying or recent use of gematotoksichny and gepatotoksichny drugs because of possible strengthening of side reactions is not recommended to accept.

The main metabolite of a leflunomid oppresses activity of CYP2C9 enzyme in this connection, at reception along with drugs which metabolism passes in connection with this fermental system (Warfarin, Phenytoinum, Tolbutamidum) development of negative effects is possible.

Terms of sale

Prescription issue.

Storage conditions

At a temperature up to 25 °C.

Period of validity

2 years.


Coincidence on the ATH code of the 4th level:

Arawa, Elafra, Leflayd, Leflunomid Kanon, Lefomid.

About Leflunomida

About drug favorable. Patients with a pseudorheumatism note its high performance and the democratic price in comparison with drug Arawa.


  • Leflunomid Kanon of 20 mg No. 30 of a tabletkikanonfarm production closed joint stock company
  • Leflunomid Kanon of 10 mg No. 30 of a tabletkikanonfarm production closed joint stock company
  • Leflunomid of 10 mg No. 30 tabletkiberezovsky pharmaceutical plant of closed joint stock company
  • Leflunomid of 20 mg No. 30 tabletkiberezovsky pharmaceutical plant of closed joint stock company
to show still
Section: For joints
in more detail

Education: Graduated from Sverdlovsk medical school (1968 - 1971) as "Paramedic". Graduated from the Donetsk medical institute (1975 - 1981) as "An epidemiologist, a hygienist". Passed postgraduate study in the Central scientific research institute of epidemiology Moscow (1986 - 1989). An academic degree – the candidate of medical sciences (degree is awarded in 1989, protection – the Central scientific research institute of epidemiology Moscow). Numerous advanced training courses are studied in epidemiology and infectious diseases.

Experience: Work as the manager of department of disinfection and sterilization of 1981 - 1992. Work as the manager of department of especially dangerous infections of 1992 - 2010. Teaching activity at Medical institute 2010 - 2013.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Leflunomid surely consult with the attending physician.